Clinical trial
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Study timeline
Study start (actual)2024-08-08Date precision: day
Registry last updated2026-05-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Recurrent Lung Non-Small Cell Carcinomaunresolved
Stage IV Lung Cancer AJCC v8unresolved
Interventions
Biospecimen CollectionPROCEDURE
Computed TomographyPROCEDURE
LymphoscintigraphyPROCEDURE
Magnetic Resonance ImagingPROCEDURE
RamucirumabBIOLOGICAL
TepotinibDRUG · verified · RxNorm: tepotinib
Sponsors & collaborators
SWOG Cancer Research Networklead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
St LouisMissouri, United States4PortlandOregon, United States4Kansas CityMissouri, United States4FlintMichigan, United States4Los AngelesCalifornia, United States3DaytonOhio, United States3SpringfieldIllinois, United States3Des MoinesIowa, United States3ChicagoIllinois, United States2San FranciscoCalifornia, United States2Las VegasNevada, United States2SacramentoCalifornia, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06031688 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.